

COLORECTAL CANCER

Frequent loss of SMAD4/DPC4 protein in colorectal cancers

R Salovaara, S Roth, A Loukola, V Launonen, P Sistonen, E Avizienyte, P Kristo, H Järvinen, S Souchelnytskyi, M Sarlomo-Rikala, L A Aaltonen

Gut 2002;51:56–59

See end of article for authors' affiliations

Correspondence to:
Dr L A Aaltonen,
Department of Medical
Genetics, Haartman
Institute, PO Box 63,
FIN-00014 University of
Helsinki, Finland;
lauri.aaltonen@helsinki.fi.

Accepted for publication
17 September 2001

Background and aims: Loss of DNA sequences from chromosome 18q21 is a major genetic change in colorectal tumorigenesis. Multiple genes have been identified in this area. One of these, *DPC4* (*deleted in pancreatic cancer 4*, also known as *SMAD4*), is mutated in a minor subset of colorectal carcinomas as well as in germlines of humans predisposed to colon tumours.

Patients and methods: The involvement of *SMAD4* in sporadic colorectal neoplasia was evaluated by immunohistochemistry in 53 unselected cases and 27 cases displaying microsatellite instability.

Results: *SMAD4* expression was absent in 20 of 53 (38%) unselected colorectal carcinomas, and reduced in another 15 (28%) cases. However, 26 of 27 cancers displaying microsatellite instability and *TGF-βIIIR* mutations were positive for *SMAD4* immunostaining.

Conclusions: Loss of *SMAD4* expression may play a more prominent role in colon cancer than anticipated based on genetic evidence, but not in mutator phenotype tumours.

Much work has focused on revealing molecular changes that occur in colorectal neoplasia. These efforts have resulted in a model for human tumour progression depicting a number of key molecular events that drive the malignant process. One of the most important events in colon cancer appears to be loss of genetic material in chromosome 18q. This change is typically found in late adenomas and carcinomas.¹ A gene termed *DCC* (*deleted in colorectal carcinoma*) has been identified through deletion mapping studies, and proposed as the target of the 18q21 deletions.² More recently, the gene *DPC4* (*deleted in pancreatic carcinoma 4*, also called *SMAD4*) was identified in 18q21.³ While this gene is frequently mutated and deleted in pancreatic carcinomas, less evidence has linked it to colorectal tumorigenesis.⁴ Although a more prominent role of *SMAD4* has been implicated in advanced disease,^{5,6} *SMAD4* has not been considered as one of the major players in colonic neoplasia, such as *APC*, *K-RAS*, and *TP53* genes.⁷ We and others recently found an association between *SMAD4* germline defects and human colon tumour susceptibility.⁸ As genes for hereditary cancer are also believed to often play a significant role in the respective sporadic tumours,^{4,7} we evaluated the role of *SMAD4* in colorectal neoplasia using immunohistochemical labelling with a monoclonal *SMAD4* antibody.⁹

MATERIALS AND METHODS

Cancer specimens

For *SMAD4* immunohistochemical labelling, 53 surgical resection specimens from unselected colorectal carcinoma patients were collected from the files of the Department of Pathology, Haartman Institute, University of Helsinki. In addition, a series of 27 archival colorectal cancer samples displaying microsatellite instability (MSI) or mutator phenotype was available from previous studies.^{10,11} The 80 tissue samples were fixed in 10% neutral buffered formalin and paraffin embedded. Haematoxylin-eosin staining was performed to allow histological characterisation. The tumours were evaluated by two pathologists. All 80 samples contained areas of normal colonic mucosa adjacent to the carcinoma (for Dukes' classification, see tables 1 and 2). The large proportion of Dukes' C and D cancers in the unselected series is due to

patient selection to the Helsinki University Hospital, and coincidence.

Of the 80 colorectal carcinomas analysed for *SMAD4* immunohistochemistry, 55 normal/tumour DNA sample pairs were available from previous studies^{10,11}; 27 MSI and 28 unselected (mostly microsatellite stable) samples, respectively. These were used for molecular genetic analyses.

Immunohistochemical labelling for SMAD4

The presence of *SMAD4* protein expression was analysed in 80 paraffin embedded specimens by immunohistochemistry. *SMAD4* monoclonal antibody raised against a peptide corresponding to amino acids 1–552 representing full length *SMAD4* of human origin (*Smad4* B-8; sc-7966; Santa Cruz Biotechnology Inc., Santa Cruz, California, USA) was used. The specificity of the antibody has been previously tested,⁹ and the specificity of the present batch was confirmed through western blotting. Western blotting of whole cell lysates of three colon carcinoma cell lines detected *SMAD4* expression in two colon carcinoma cell lines; HCT116 and DLD1 displayed the correct sized band without background. No expression was observed in the cell line SW480. The *SMAD4* expression status of these cell lines was confirmed using reverse transcription-polymerase chain reaction (RT-PCR) analysis and immunohistochemistry. Human *HPRT* control amplicon set (Clontech, Palo Alto, California, USA) was used as a positive control for RT-PCR (data not shown).

Unstained 4 μm tissue sections from the 80 paraffin embedded cancer specimens were mounted on slides coated with 3-aminopropyl-triethoxy-silane (Sigma, St Louis, Missouri, USA). Sections were deparaffinised in xylene, and rehydrated through a graded alcohol series to distilled water. After deparaffinisation the sections were pretreated in a microwave oven in buffered sodium citrate. For immunohistochemical

Abbreviations: MSI, microsatellite instability; LOH, loss of heterozygosity; RT-PCR, reverse transcription-polymerase chain reaction; *TGF-βIIIR*, transforming growth factor β type II receptor.

Table 1 SMAD4 immunohistochemical labelling results for 53 unselected colorectal cancers

Labelling	Normal mucosa	Carcinoma	Dukes' classification			
			A	B	C	D
+++	29	8	1	3	0	4
++	17	10	2	2	2	4
+	7	15	0	5	7	3
-	0	20	0	5	11	4
Total	53	53	3	15	20	15




Figure 1 (A) SMAD4 immunohistochemical labelling of the normal colon. Epithelial staining was equally distributed. Nuclear as well as cytoplasmic staining was seen. (B) Examples of SMAD4 immunohistochemical expression in three colon carcinomas with a characteristic positive staining pattern (+++) in normal mucosal epithelial cells. Protein expression was lost (-) (top panels), slightly diminished (++) (middle panels), or maintained (+++) (bottom panels). The lesion with maintained expression displayed microsatellite instability.

analysis, the avidin-biotin complex immunoperoxidase technique was undertaken using the commercial Elite ABC kit (Vectastain; Vector Laboratories, Burlingame, California, USA).

Endogenous peroxidase was blocked by incubating in hydrogen peroxidase with methanol and then incubating with non-immune horse serum. Also, endogenous biotin was blocked (avidin-biotin blocking kit, SP-2001; Vector Laboratories). Slides were labelled with a 1:2000 dilution of the primary antibody and incubated overnight. Sections were then incubated in biotinylated second antibody and peroxidase labelled avidin-biotin complex for 30 minutes. All dilutions were made using phosphate buffered saline (pH 7.2). Incubations were carried out in humid chambers at room temperature. Staining was visualised using a 3-amino-9-

ethylcarbazole (Sigma) solution for 15 minutes at room temperature, and sections were counterstained in Mayer's haematoxylin, rinsed in water, and mounted in aqueous mounting media. SMAD4 antigen expression was analysed by two pathologists. The percentage of positive cells was evaluated and scored as follows: (-) <5%, (+) 5–9%, (++) 10–34%, and (+++) ≥35% (fig 1).

18q21 loss of heterozygosity analysis

Loss of heterozygosity (LOH) analysis was performed using two fluorescent labelled microsatellite markers (D18S1156 and D18S363). PCR reactions were carried out in a 20 µl reaction volume containing 100 ng genomic DNA, 1×PCR buffer (Applied Biosystems, Foster City, California, USA), 250 µM of each dNTP (Finnzymes, Espoo, Finland), 0.5 µM of each primer, and 2 units of AmpliTaqGold polymerase (Applied Biosystems). MgCl₂ concentration was 2 mM. The following PCR cycles were used for amplification: 10 minutes at 95°C, 30 cycles of 45 seconds at 95°C, 45 seconds at 54°C, and one minute at 72°C. Final extension was 10 minutes at 72°C. PCR products were loaded onto 6% polyacrylamide gels and run on an ABI PRISM 377 DNA Sequencer (Applied Biosystems). The data were collected automatically and analysed by GeneScan 3.1 software (Applied Biosystems). LOH was scored by calculating the ratio of the peak areas of the constitutional alleles, $L = (a_1 \times a_{n1}) / (a_2 \times a_{n2})$. If $L < 0.6$ or $L > 1.67$, one of the tumour alleles had decreased by more than 40%, implicating LOH.

TGF-βIIIR mutation analysis

The polyA tract in the coding region of the *transforming growth factor β type II receptor (TGF-βIIIR)* gene was scrutinised for deletions by PCR amplification using fluorescent labelled primers and subsequent fragment analysis by an automated sequencer. The PCR reactions were carried out in a 10 µl reaction volume including 100 ng genomic DNA, 1×PCR reaction buffer (PE/ABI), 200 µM of each dNTP (Finnzymes), 0.3 µM of each primer, and 1.5 units of AmpliTaqGOLD polymerase (PE/ABI). MgCl₂ concentration was 1.5 mM. The following PCR cycles were used for amplification: 10 minutes at 94°C, 28 cycles of 30 seconds at 94°C, 75 seconds at 55°C, and 30 seconds at 72°C. The forward (F) and reverse (R) primers were: F: 5'-CTT TATTCTGGAAGATGCTG; R: 5'-GAAGAAAGTCTCACCAGGC.

RESULTS AND DISCUSSION

SMAD4 immunostaining in unselected colorectal carcinomas

Normal colonic mucosa displayed positive staining in all cases. Seven of 53 were scored as (+) and the remaining 46 as (++) or (+++) (table 1). Nuclear as well as cytoplasmic staining was seen, similar to the pattern recently reported.⁹ Epithelial staining was typically equally distributed (fig 1A) but occasionally stronger staining was observed in the bottom of the crypts. This differs from a recent study using a different SMAD4 antibody where stronger staining was detected in the apical side.¹²

Table 2 SMAD4 immunohistochemical labelling results for 27 colorectal cancers with microsatellite instability

Labelling	Normal mucosa	Carcinoma	Dukes' classification			
			A	B	C	D
+++	18	16	3	7	5	1
++	8	10	0	7	1	2
+	1	0	0	0	0	0
-	0	1	0	1	0	0
Total	27	27	3	15	6	3

Compared with results from normal mucosa, SMAD4 staining was frequently absent in carcinomas ($p < 0.0001$, Fisher's exact test). Sixty six per cent (35 of 53) of unselected colorectal adenocarcinomas displayed absent (-) (20 of 53, 38%) or decreased (+) (15 of 53, 28%) staining. In 18 of 53 (34%) carcinomas, SMAD4 expression comparable with normal tissue expression (++ to +++) was observed (table 1, fig 1B).

Correlation between SMAD4 immunostaining and microsatellite marker analyses

Twenty seven samples showing MSI were originally selected for SMAD4 immunostaining based on previous MSI data.^{10, 11} MSI tumours frequently display inactivating mutations of the *TGF-βIIIR* gene; deletions in a polyA microsatellite tract in the coding region of *TGF-βIIIR* in particular are characteristic of these lesions.¹³ In agreement with previous observations, in our series 21 of 25 (84%) tumours available for analysis displayed a protein truncating mutation in the *TGF-βIIIR* polyA tract (not shown). Unlike most colorectal cancers, MSI tumours are typically diploid, and rarely display gross chromosomal rearrangements, such as deletions.^{14, 15} We next examined SMAD4 immunostaining in the 27 MSI colorectal cancers. The immunostaining results in this series of tumours were strikingly different from the unselected carcinomas ($p < 0.0009$, Fisher's exact test): 26 of 27 (96%) MSI cancers had SMAD4 expression, comparable with normal tissue, while one (4%) displayed no staining (table 2).

LOH data were created with 18q21 microsatellite markers D18S1156 and D18S363 (see methods). This analysis focused on 28 unselected tumours (table 3). Also, MSI samples were included in the analysis but 88% of the results were uninformative because of aberrant MSI alleles or homozygosity (data not shown). LOH status of the unselected tumours did not have an effect on the SMAD4 immunostaining results (table 3). Most unselected tumours (15 of 22 (68%) informative cases) displayed evidence of deletions. Deletions were equally present in tumours with reduced (- or +) and normal (++ or +++) SMAD4 staining (table 3).

Previous studies have confirmed the role of *SMAD4* in colorectal tumorigenesis in a subset of these lesions.⁴ The extent of this contribution however has been more ambiguous. While the first estimates of *SMAD4* mutation frequency in colon cancer were low,⁴ it seems that in metastasised disease the mutation rate is higher.⁷ The frequency of *SMAD4* mutations has been found to increase from 0% in adenomas to 10% in carcinomas, and up to 35% in invasive carcinomas with metastases.³ A similar but not significant tendency towards loss of SMAD4 protein in metastatic disease can also be observed in the unselected tumour series; 43% in Dukes' C and D cancers combined. That only four of 15 (27%) Dukes' D carcinomas were SMAD4 negative may be due to the small numbers. SMAD4 was relatively frequently lost in localised disease also (28% in Dukes' A and B) (table 1). These values are higher than those reported by Maitra and colleagues¹⁶ using the same antibody. The difference may arise from a different scoring

Table 3 18q21 LOH analysis of the 28 unselected colorectal carcinomas where normal/tumour DNA pairs were available.

Case	D18S1156	D18S363	IHC
C964	-	LOH	Neg
C972	LOH	LOH	Neg
C986	-	N	Neg
C978	-	N	Neg
C989	-	LOH	Neg
C1038	N	-	Neg
C1051	-	-	Neg
C1079	-	N	Neg
C1086	N	N	Neg
C977	N	LOH	+
C981	LOH	LOH	+
C982	-	LOH	+
C984	-	-	+
C1064	-	-	+
C1084	LOH	-	+
C1091	N	LOH	+
C1089	LOH	N	+
C1088	-	LOH	+
C980	-	N	++
C1047	LOH	-	++
C1048	-	-	++
C1066	-	-	++
C1083	-	-	++
C965	-	LOH	+++
C1074	N	LOH	+++
C1077	LOH	MSI	+++
C1080	N	N	+++
C1085	-	LOH	+++

-, uninformative or failed amplifications; N, heterozygous unchanged loci; LOH, loss of heterozygosity; MSI, microsatellite instability; IHC, immunohistochemistry.

system, in addition to technical matters and true differences between the respective study materials. In our study, tumours displaying positive staining in less than 5% of tumour cells were classified as negative whereas in the study of Maitra and colleagues¹⁶ any positivity was taken into account.

Our study suggests that SMAD4 expression is more frequently lost during colorectal tumorigenesis than anticipated previously (almost 40% of our unselected series). In addition, reduced expression was detected in 28%. The latter may be of significance as it is possible that heterozygous loss of *SMAD4* and the consequent decrease in expression contributes to malignant growth.¹⁷

Prominent expression of SMAD4 in MSI colorectal cancers is conceivable as both SMAD4 and TGF-βIIIR contribute to tumour suppressive effects as members of the TGF-β signalling pathway¹⁸ although BMP signalling may also contribute to colorectal tumorigenesis through SMAD4.¹⁹ While genomic deletions and somatic mutations explain for the most part loss of SMAD4 in colon cancers, the mechanism of complete SMAD4 loss in 38% of an unselected tumour series and lack of correlation between LOH and reduction of

staining remain somewhat obscure. Possible additional inactivation mechanisms include promoter area mutations and epigenetic changes such as hypermethylation. In a separate work, we found no evidence of these in *SMAD4*.²⁰ Downregulated expression through transcription factors secondary to genetic events elsewhere, similar to recent findings on the background of c-MYC overexpression in colorectal cancer due to *APC* mutations,²¹ is also possible.

While we cannot exclude the possibility that decreased SMAD4 levels are simply due to frequent deletions in 18q21 targeted to other tumour suppressor genes, we propose that SMAD4 loss is likely to be a key event in colorectal tumorigenesis. Firstly, *SMAD4* is somatically inactivated in a number of colorectal tumours. In addition to deletions, frameshift mutations as well as point mutations that have functional consequences have been described, convincingly demonstrating that specific genetic changes occur in *SMAD4* in tumorigenesis.^{3 17 18 22 23} Secondly, the role of *SMAD4* in intestinal tumorigenesis has been demonstrated through studies linking germline *SMAD4* defects to intestinal tumour susceptibility, in animal models as well as in humans.^{8 23} Thirdly, SMAD4 function has been elucidated in great detail, although functions as yet unknown may exist. The present data provide a firm base for the hypothesis that SMAD4 is a key molecule in pathways involved in cell growth control.¹⁸ Fourthly, our data show that a decrease and complete loss of *SMAD4* expression is a frequent phenomenon in colorectal carcinogenesis. The data presented here suggest a more prominent role of SMAD4 in colorectal cancer than anticipated based on genetic evidence.

ACKNOWLEDGEMENTS

We thank Siv Lindroos, Sinikka Lindh, Kirsi Laukkanen, Inga-Lill Svedberg, Annika Lahti, and Anitta Hottinen for technical assistance, and Heikki Joensuu for advice on statistics. Supported by grants from the Academy of Finland (44870), Finnish Centre of Excellence Programme 2000–2005), Finnish Cancer Societies, Sigrid Juselius Foundation, Emil Aaltonen Foundation, Helsinki University Central Hospital, Biocentrum Helsinki, and the European Commission Contract BMH4-CT98-3865.

Authors' affiliations

R Salovaara, Department of Medical Genetics and Department of Pathology, Haartman Institute, PO Box 63, FIN-00014 University of Helsinki, Finland

S Roth, A Loukola, V Launonen, E Avizienyte, P Kristo, Department of Medical Genetics, Haartman Institute, PO Box 63, FIN-00014 University of Helsinki, Finland

P Sistonen, Finnish Red Cross Blood Transfusion Service, Kivihaantie 7, FIN-00310 Helsinki, Finland

H Järvinen, Second Department of Surgery, Helsinki University Central Hospital, PO Box 340, FIN-00029 Helsinki, Finland

S Souchelnytskyi, Ludwig Institute for Cancer Research, PO Box 595, S-751 24 Uppsala, Sweden

M Sarlomo-Rikala, Department of Pathology, Haartman Institute, PO

Box 63, FIN-00014 University of Helsinki, Finland

L A Aaltonen, Department of Medical Genetics, Haartman Institute, PO Box 63, FIN-00014 University of Helsinki, Finland, and Department of Oncology, Helsinki University Central Hospital, PO Box 180, FIN-00029 Helsinki, Finland

REFERENCES

- Vogelstein B**, Fearon ER, Hamilton SR, *et al.* Genetic alterations during colorectal tumor development. *N Engl J Med* 1988;**319**:525–32.
- Fearon E**, Cho K, Nigro J, *et al.* Identification of a chromosome 18q gene that is altered in colorectal cancers. *Science* 1990;**247**:49–56.
- Hahn SA**, Schutte M, Hoque ATMS, *et al.* *DPC4*, a candidate tumor suppressor gene at human chromosome 18q21.1. *Science* 1996;**271**:350–3.
- Thiagalingam S**, Lengauer C, Leach FS, *et al.* Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. *Nat Genet* 1996;**13**:343–6.
- Miyaki M**, Iijima T, Konishi M, *et al.* Higher frequency of *Smad4* gene mutation in human colorectal cancer with distant metastasis. *Oncogene* 1999;**20**:3098–103.
- Koyama M**, Ito M, Nagai H, *et al.* Inactivation of both alleles of the *DPC4/SMAD4* gene in advanced colorectal cancers: identification of seven novel somatic mutations in tumours from Japanese patients. *Mutat Res* 1999;**406**:71–7.
- Kinzler KW**, Vogelstein B. Lessons from hereditary colorectal cancer. *Cell* 1996;**280**:159–70.
- Howe JR**, Roth S, Ringold JC, *et al.* Mutations in the *SMAD4/DPC4* gene in juvenile polyposis. *Science* 1998;**280**:1086–8.
- Wilentz RE**, Su GH, Dai JL, *et al.* Immunohistochemical labeling for *Dpc4* mirrors genetic status in pancreatic adenocarcinomas. A new marker of *DPC4* inactivation. *Am J Pathol* 2000;**156**:37–43.
- Aaltonen LA**, Salovaara R, Kristo P, *et al.* Incidence of hereditary nonpolyposis colorectal cancer, and molecular screening for the disease. *N Engl J Med* 1998;**338**:1481–7.
- Salovaara R**, Loukola A, Kristo P, *et al.* Population-based molecular detection of hereditary nonpolyposis colorectal cancer. *J Clin Oncol* 2000;**18**:2193–200.
- Korchynskyi O**, Landström M, Stoika R, *et al.* Expression of SMAD proteins in human colorectal cancers. *Int J Cancer* 1999;**82**:197–202.
- Markowitz S**, Wang J, Myeroff L, *et al.* Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. *Science* 1995;**268**:1336–8.
- Aaltonen LA**, Peltomäki P, Leach FS, *et al.* Clues to the pathogenesis of familial colorectal cancer. *Science* 1993;**260**:812–16.
- Thibodeau SN**, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. *Science* 1993;**260**:816–19.
- Maitra A**, Molberg K, Albores-Saavedra J, *et al.* Loss of *Dpc4* expression in colonic adenocarcinomas correlates with the presence of metastatic disease. *Am J Pathol* 2000;**157**:1105–11.
- Xiaoling Xu**, Brodie SG, Yang X, *et al.* Haploid loss of the tumor suppressor *Smad4/Dpc4* initiates gastric polyposis and cancer in mice. *Oncogene* 2000;**19**:1868–74.
- Heldin CH**, Miyazono K, ten Dijke P. TGF-beta signaling from cell membrane to nucleus through SMAD proteins. *Nature* 1997;**390**:465–71.
- Howe JR**, Bair JL, Sayed MG, *et al.* Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. *Nat Genet* 2001;**28**:184–7.
- Roth S**, Laiho P, Salovaara R, *et al.* No *SMAD4* hypermethylation in colorectal cancer. *Br J Cancer* 2000;**83**:1015–19.
- He TC**, Sparks AB, Rago C, *et al.* Identification of c-MYC as a target of the APC pathway. *Science* 1998;**281**:1509–12.
- Shi Y**, Hata A, Lo RS, *et al.* A structural basis for mutational inactivation of the tumour suppressor *Smad4*. *Nature* 1997;**388**:87–93.
- Takaku K**, Oshima M, Miyoshi H, *et al.* Intestinal tumorigenesis in compound mutant mice of both *Dpc4 (Smad4)* and *Apc* genes. *Cell* 1998;**92**:645–56.